Toleranzia AB
Toleranzia AB (publ), a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate in clinical trial for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate for the treatment of ANCA vasculitis, an autoimmune blood vessel disease. In … Read more
Toleranzia AB (TOL) - Total Assets
Latest total assets as of June 2025: Skr183.41 Million SEK
Based on the latest financial reports, Toleranzia AB (TOL) holds total assets worth Skr183.41 Million SEK as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Toleranzia AB - Total Assets Trend (2012–2024)
This chart illustrates how Toleranzia AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Toleranzia AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Toleranzia AB's total assets of Skr183.41 Million consist of 8.3% current assets and 91.7% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 7.4% |
| Accounts Receivable | Skr1.66 Million | 0.9% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr170.74 Million | 91.6% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Toleranzia AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Toleranzia AB's current assets represent 8.3% of total assets in 2024, a decrease from 100.0% in 2012.
- Cash Position: Cash and equivalents constituted 7.4% of total assets in 2024, down from 86.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 91.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 91.6% of total assets.
Toleranzia AB Competitors by Total Assets
Key competitors of Toleranzia AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Toleranzia AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Toleranzia AB generates 0.16x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Toleranzia AB is currently not profitable relative to its asset base.
Toleranzia AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.71 | 0.63 | 19.82 |
| Quick Ratio | 0.71 | 0.70 | 19.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr-1.30 Million | Skr -1.95 Million | Skr 46.02 Million |
Toleranzia AB - Advanced Valuation Insights
This section examines the relationship between Toleranzia AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.74 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 16.2% |
| Total Assets | Skr186.47 Million |
| Market Capitalization | $9.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values Toleranzia AB's assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Toleranzia AB's assets grew by 16.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Toleranzia AB (2012–2024)
The table below shows the annual total assets of Toleranzia AB from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr186.47 Million | +16.24% |
| 2023-12-31 | Skr160.43 Million | +27.70% |
| 2022-12-31 | Skr125.63 Million | -4.99% |
| 2021-12-31 | Skr132.23 Million | +82.20% |
| 2020-12-31 | Skr72.58 Million | +87.77% |
| 2019-12-31 | Skr38.65 Million | +27.20% |
| 2018-12-31 | Skr30.39 Million | +81.18% |
| 2017-12-31 | Skr16.77 Million | -24.73% |
| 2016-12-31 | Skr22.28 Million | -18.24% |
| 2015-12-31 | Skr27.26 Million | +769.25% |
| 2014-12-31 | Skr3.14 Million | +73.78% |
| 2013-12-31 | Skr1.80 Million | -4.94% |
| 2012-12-31 | Skr1.90 Million | -- |